2023-10-18 18:58:58
The bivariate vaccine ARVAC Cecilia Grierson against COVID-19, created by Scientists from the University of San Martín in conjunction with researchers from the CONICET, It was approved by the National Administration of Medicines, Food and Medical Technology (ANMAT) and can be used as a booster for people over 18 years of age. The presentation took place at a press conference where the nation’s Minister of Health, Carla Vizzotti and her counterpart from Science, Technology and Innovation, Daniel Filmus and specialists participated.
In an event held in the Malvinas Argentinas hall, located in the Scientific and Technological Pole of the City of Buenos Aires, the vaccine was presented to society. ARVAC Cecilia Grierson. This vaccine had a possible development from a public-private consortium that included more than 600 scientists and professionals, 25 institutions and 2,094 volunteers.
While some political sectors tried to question CONICET, scientists responded with facts. The first post came through the Agency for Science, Technology and Society, which celebrated through a post on Twitter: “In what is probably the scientific event of the year: they announce the approval by the ANMAT of the “ARVAC vaccine, the first 100% Argentine vaccine against #COVID, developed by the University of San Martín.”
The director of Conicet responded to Milei: “It is the most serious attack we have suffered”
For her part, the Minister of Health of the Nation, Carla Vizzotti published on her X account: “We have an Argentine vaccine against COVID-19. It is a historical milestone for our country. “ANMAT approved the ARVAC Cecilia Grierson bivariate vaccine to be used as a booster.” And she concluded: “The future is with more science, more national production and more public health.”
It is the first inoculant created and manufactured 100% Argentine, and with an efficient scientific line of public-private work from its discovery to its production. Furthermore, it is an innovative export product for the region and the world.
In the same sense, Daniel Filmus, Minister of Science, Technology and Innovation of the Nation and CONICET researcher cataloged this event as a “historic day” and added: “Together with Carla Vizzotti, we presented the Argentine vaccine “ARVAC Cecilia Grierson” against COVID-19, approved by ANMAT. “It will be used as a reinforcement for those over 18 years of age.”
National Production
The ARVAC Cecilia Grierson vaccine, developed by the National University of San Martín, CONICET and the Cassará Laboratory, and promoted from the first moment by the Science, Technology and Innovation portfolio and the National Agency for the Promotion of Research, Technological Development and Innovation (R&D&i Agency), proved to be safe and effective as a booster against the SARS-CoV-2 virus in people over 18 years of age.
The Argentine vaccine, closer to achieving approval
This inoculation against COVID-19 stands out for being bivalent. That is, it contains two different antigens that give it a superior ability to neutralize the current variants of the SARS-CoV-2 virus, including Ómicron, its subvariants, Gamma and the original version from Wuhan. Among its key aspects, the ARVAC Cecilia Grierson is classified as second generation.
In addition, it has a design based on recombinant proteins, similar to vaccines against HPV cervical cancer and Hepatitis B. Both are administered in Argentina, especially to children and adolescents. The Hepatitis B vaccine, for example, has been used in newborns for more than two decades.
The Argentine Arvac Cecilia Grierson vaccine against Covid-19 is “safe and very immunogenic”
Another positive aspect of this Argentine invention is its technology applied to conservation. This vaccine does not require the deep-freezing process that others of its type do, but with a standard cold chain, between 2 and 8°C, it can be stored without problems for half a year. Once opened, it must be applied within the next 24 hours.
In the midst of complaints against the Organization dedicated to the promotion of science and technology in Argentina, CONICET, scientists responded with a historical fact that removes the questions from the roots.
NT/fl
#Historical #milestone #Argentina #produced #vaccine #Covid19